Concepedia

HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients

Arezoo Marjani, Farah Bokharaei‐Salim, Fatemeh Jahanbakhshi, Seyed Hamidreza Monavari, Maryam Esghaei, Saeed Kalantari, Seyed Jalal Kiani, Angila Ataei‐Pirkooh, Atousa Fakhim, Hossein Keyvani

Archives of Virology · 2019 · 13 citations · 60 references

DOI

Concepts

References

60

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Diana Finzi, Joel N. Blankson, Janet D. Siliciano et al. · Nature Medicine · 1999 · 2.1K citations

, , +17

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

Diane Bennett, Ricardo Camacho, Dan Oţelea et al. · PLoS ONE · 2009 · 960 citations · Full text

, , +17

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Sharon Walmsley, Antonio Antela, Nathan Clumeck et al. · New England Journal of Medicine · 2013 · 878 citations · Full text

, , +17

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 546 citations · Full text

, , +12

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 514 citations · Full text

, , +16